Crossmark

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review

Crossref DOI link: https://doi.org/10.1007/s40273-024-01362-2

Published Online: 2024-03-15

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raad, Angie

Rizzo, Maria

Appiah, Katherine

Kearns, Isabella

Hernandez, Luis https://orcid.org/0000-0002-9532-546X
License Information

Text and Data Mining valid from 2024-03-15

Version of Record valid from 2024-03-15
More Information

Article History

Accepted: 11 February 2024

First Online: 15 March 2024

Declarations

:

: This study was funded by Takeda Pharmaceuticals America, Inc.

: Angie Raad, Maria Rizzo and Katherine Appiah are full-time employees of Cytel. Isabella Kearns is a full-time employee of Takeda UK Ltd, and Luis Hernandez is a full-time employee of Takeda Pharmaceuticals America, Inc. This article reflects the views and opinions of the authors and not necessarily those of the organizations to which individuals are affiliated.

: The authors declare that all the data supporting the findings of this study (i.e., the information extracted from the studies included in this review) are available within the article and the Online Resource.

: All authors contributed to the study design, literature search, and writing, review and approval of the manuscript.

Document is current

Any future updates will be listed below